

Merryn Voysey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633795/publications.pdf>

Version: 2024-02-01

110
papers

18,014
citations

76196

40
h-index

27345

106
g-index

117
all docs

117
docs citations

117
times ranked

27064
citing authors

#	ARTICLE	IF	CITATIONS
1	The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. <i>Vaccine</i> , 2022, 40, 450-458.	1.7	10
2	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. <i>Lancet, The</i> , 2022, 399, 521-529.	6.3	314
3	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
4	Melatonin In Acute Mania Investigation (MIAMIâ€šUK). A randomized controlled trial of addâ€šon melatonin in bipolar disorder. <i>Bipolar Disorders</i> , 2021, 23, 176-185.	1.1	5
5	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
6	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
7	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
8	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
9	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
10	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
11	Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 937-943.	1.1	0
12	A Bayesian approach for estimating typhoid fever incidence from largeâ€šscale facilityâ€šbased passive surveillance data. <i>Statistics in Medicine</i> , 2021, 40, 5853-5870.	0.8	8
13	Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. <i>Lancet, The</i> , 2021, 398, 675-684.	6.3	77
14	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV,the</i> , 2021, 8, e474-e485.	2.1	190
15	Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination. <i>Frontiers in Tropical Diseases</i> , 2021, 2, .	0.5	2
16	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV,the</i> , 2021, 8, e568-e580.	2.1	124
17	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€šspecific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
18	Impact of Vaccination on <i>Haemophilus influenzae</i> Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal. <i>Journal of Infectious Diseases</i> , 2021, 224, S267-S274.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
20	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
21	Diagnostic accuracy of Fever-PAIN and Centor criteria for bacterial throat infection in adults with sore throat: a secondary analysis of a randomised controlled trial. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0122.	0.9	5
22	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
23	Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. <i>Lancet, The</i> , 2021, 398, 1683-1684.	6.3	47
24	Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. <i>The Lancet Global Health</i> , 2021, 9, e1561-e1568.	2.9	48
25	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. <i>Nature Communications</i> , 2021, 12, 6370.	5.8	3
26	Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. <i>The Lancet Global Health</i> , 2021, 9, e1688-e1696.	2.9	42
27	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
28	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
29	The Surveillance for Enteric Fever in Asia Project (SEAP), Severe Typhoid Fever Surveillance in Africa (SETA), Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRATAA) Population-based Enteric Fever Studies: A Review of Methodological Similarities and Differences. <i>Clinical Infectious Diseases</i> , 2020, 71, S102-S110.	2.9	36
30	Under-detection of blood culture-positive enteric fever cases: The impact of missing data and methods for adjusting incidence estimates. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007805.	1.3	14
31	Homologous and heterologous re-challenge with <i>Salmonella Typhi</i> and <i>Salmonella Paratyphi A</i> in a randomised controlled human infection model. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008783.	1.3	15
32	Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, S74-S82.	2.9	32
33	The Design and Analysis of Seroefficacy Studies for Typhoid Conjugate Vaccines. <i>Clinical Infectious Diseases</i> , 2019, 68, S183-S190.	2.9	4
34	Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, S67-S73.	2.9	17
35	Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal. <i>Clinical Infectious Diseases</i> , 2019, 68, S138-S145.	2.9	7
36	Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002771.	3.9	56

#	ARTICLE	IF	CITATIONS
37	Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. <i>New England Journal of Medicine</i> , 2019, 381, 2209-2218.	13.9	147
38	Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. <i>Lancet Infectious Diseases</i> , 2019, 19, 156-164.	4.6	8
39	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. <i>Clinical Infectious Diseases</i> , 2019, 68, 1265-1273.	2.9	26
40	Assessment of an Antibody-in-Lymphocyte Supernatant Assay for the Etiological Diagnosis of Pneumococcal Pneumonia in Children. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 459.	1.8	3
41	Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). <i>Clinical Infectious Diseases</i> , 2018, 67, 18-24.	2.9	55
42	Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries. <i>Clinical Infectious Diseases</i> , 2018, 66, 913-920.	2.9	42
43	Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review. <i>Clinical Trials</i> , 2018, 15, 278-285.	0.7	17
44	Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e103-e106.	1.1	2
45	Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias. <i>PLoS ONE</i> , 2018, 13, e0202517.	1.1	4
46	Mixed effects approach to the analysis of the stepped wedge cluster randomised trial—Investigating the confounding effect of time through simulation. <i>PLoS ONE</i> , 2018, 13, e0208876.	1.1	34
47	Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences. <i>PLoS ONE</i> , 2018, 13, e0196200.	1.1	0
48	Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. <i>Vaccine</i> , 2017, 35, 2701-2708.	1.7	8
49	An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence. <i>Clinical Infectious Diseases</i> , 2017, 64, 1604-1611.	2.9	54
50	Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1535.	3.8	29
51	The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses. <i>JAMA Pediatrics</i> , 2017, 171, 637.	3.3	332
52	Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara—Vectored Ebola Vaccines at 1 Year. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1075.	3.8	67
53	Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age—a phase 3 extension to a randomised controlled trial. <i>Vaccine</i> , 2017, 35, 395-402.	1.7	19
54	Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. <i>Vaccine</i> , 2017, 35, 5850-5857.	1.7	22

#	ARTICLE	IF	CITATIONS
55	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. <i>Cmaj</i> , 2017, 189, E1276-E1285.	0.9	13
56	Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e130-e135.	1.1	10
57	Identification of Novel Serodiagnostic Signatures of Typhoid Fever Using a Salmonella Proteome Array. <i>Frontiers in Microbiology</i> , 2017, 8, 1794.	1.5	32
58	Assessment and Translation of the Antibody-in-Lymphocyte Supernatant (ALS) Assay to Improve the Diagnosis of Enteric Fever in Two Controlled Human Infection Models and an Endemic Area of Nepal. <i>Frontiers in Microbiology</i> , 2017, 8, 2031.	1.5	13
59	Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2017, 14, e1002398.	3.9	142
60	Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. <i>Clinical Infectious Diseases</i> , 2017, 64, 1066-1073.	2.9	60
61	Non-specific immunological effects of selected routine childhood immunisations: systematic review. <i>BMJ</i> , The, 2016, 355, i5225.	3.0	69
62	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004926.	1.3	67
63	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 787-793.	1.1	14
64	Factors influencing women's attitudes towards antenatal vaccines, group B <i>Streptococcus</i> and clinical trial participation in pregnancy: an online survey. <i>BMJ Open</i> , 2016, 6, e010790.	0.8	34
65	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. <i>Vaccine</i> , 2016, 34, 6350-6357.	1.7	0
66	Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e113-e123.	1.1	27
67	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectors for Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	3.8	266
68	The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials. <i>Vaccine</i> , 2016, 34, 3986-3992.	1.7	5
69	Psychoeducation and online mood tracking for patients with bipolar disorder: A randomised controlled trial. <i>Journal of Affective Disorders</i> , 2016, 205, 245-251.	2.0	25
70	The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children. <i>Vaccine</i> , 2016, 34, 4221-4228.	1.7	10
71	Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2016, 6, e011680.	0.8	11
72	Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. <i>Vaccine</i> , 2016, 34, 1657-1664.	1.7	38

#	ARTICLE	IF	CITATIONS
73	Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2â€–2 factorial randomised trial. <i>Lancet Psychiatry</i> , 2016, 3, 31-39.	3.7	84
74	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	1.1	2
75	Live attenuated oral vaccine, age and anti-Vi antibody status at baseline significantly affect attack rate in a human <i>Salmonella Typhi</i> challenge model. <i>Journal of Infection</i> , 2015, 71, 689.	1.7	0
76	Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. <i>BMJ Open</i> , 2015, 5, e008748.	0.8	49
77	Applying the intention-to-treat principle in practice: Guidance on handling randomisation errors. <i>Clinical Trials</i> , 2015, 12, 418-423.	0.7	47
78	Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey. <i>Vaccine</i> , 2015, 33, 7203-7210.	1.7	0
79	Immunological effect of administration of sequential doses of <i>Haemophilus influenzae</i> type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 172-180.	4.6	9
80	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174â€–000 participants in 27 randomised trials. <i>Lancet</i> , 2015, 385, 1397-1405.	6.3	1,112
81	Understanding paratyphoid infection: study protocol for the development of a human model of <i>Salmonella enterica</i> serovar Paratyphi A challenge in healthy adult volunteers. <i>BMJ Open</i> , 2015, 5, e007481-e007481.	0.8	16
82	Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. <i>Vaccine</i> , 2015, 33, 4579-4585.	1.7	11
83	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. <i>BMJ</i> , 2015, 350, h1554-h1554.	3.0	27
84	Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 405-414.	4.6	22
85	Effect of nasal balloon autoinflation in children with otitis media with effusion in primary care: an open randomized controlled trial. <i>Cmaj</i> , 2015, 187, 961-969.	0.9	35
86	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. <i>Journal of Infection</i> , 2015, 71, 43-52.	1.7	61
87	Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-184.	1.3	30
88	An open randomised study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in primary care. <i>Health Technology Assessment</i> , 2015, 19, 1-150.	1.3	17
89	Oral corticosteroid use for clinical and cost-effective symptom relief of sore throat: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 365.	0.7	4
90	Self-harm in people with epilepsy: A retrospective cohort study. <i>Epilepsia</i> , 2014, 55, 1355-1365.	2.6	21

#	ARTICLE	IF	CITATIONS
91	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 865-873.	1.2	30
92	Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 760-766.	1.1	34
93	Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 857-864.	1.2	32
94	The Effect of Chronic Cytomegalovirus Infection on Pneumococcal Vaccine Responses. <i>Journal of Infectious Diseases</i> , 2014, 209, 1635-1641.	1.9	19
95	External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. <i>BMC Medical Research Methodology</i> , 2014, 14, 40.	1.4	483
96	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e91413.	1.1	12
97	Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial. <i>Lancet</i> , The, 2013, 381, 1627-1633.	6.3	298
98	Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. <i>Oncologist</i> , 2013, 18, 1221-1228.	1.9	30
99	Treatment of child anxiety disorders via guided parent-delivered cognitive-behavioural therapy: Randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013, 203, 436-444.	1.7	107
100	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	1.1	80
101	Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1165-1170.	4.3	33
102	Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. <i>Clinical Cancer Research</i> , 2012, 18, 3188-3196.	3.2	63
103	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012, 163, 508-514.	1.2	24
104	Repeat prenatal corticosteroid prior to preterm birth: a systematic review and individual participant data meta-analysis for the PRECISE study group (prenatal repeat corticosteroid international IPD) <i>Tj ETQq0 0 0 rgBT, Overlock, 10 Tf 50 2</i> <i>Reviews</i> , 2012, 1, 12.	2.5	17
105	Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials. <i>Pediatrics</i> , 2011, 128, 729-739.	1.0	136
106	Simulation of Quality-Adjusted Survival in Chronic Diseases. <i>Medical Decision Making</i> , 2011, 31, 559-570.	1.2	7
107	Inhaled Nitric Oxide in preterm infants: a systematic review and individual patient data meta-analysis. <i>BMC Pediatrics</i> , 2010, 10, 15.	0.7	29
108	The Early Prevention of Obesity in Children (EPOCH) Collaboration - an Individual Patient Data Prospective Meta-Analysis. <i>BMC Public Health</i> , 2010, 10, 728.	1.2	43

#	ARTICLE	IF	CITATIONS
109	A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials. PLoS ONE, 2010, 5, e8580.	1.1	17
110	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet, The, 2009, 373, 1780-1788.	6.3	270